Please login to the form below

Inlyta

This page shows the latest Inlyta news and features for those working in and with pharma, biotech and healthcare.

Keytruda combo outshines Opdivo in kidney cancer

Topline results from the Phase 3 Keynote-426 trial of Keytruda Inlyta in first-line RCC showed an overall response rate (ORR) of 59.3% with 47% less risk of death ... There is another contender in the checkpoint inhibitor field which could play a role:

Latest news

EU approval for Opdivo combo in renal cell cancer

VEGF-targeting Inlyta (axitinib).
Roche pulls EU Tecentriq/Avastin filing in kidney cancer

inhibitor Keytruda (pembrolizumab) from Merck &Co/MSD, including impressive survival data in combination with Pfizer’s Inlyta (axitinib) in the phase 3 KEYNOTE-426 trial reported at this year’s ESMO
BMS CEO tackles investor ‘frustrations’ on immuno-oncology

inhibitor Bavencio (avelumab) – both given in tandem with Pfizer’s tyrosine kinase inhibitor Inlyta (axitinib) – leading to them being touted as a potential new treatment standard for these patients.
Keytruda hits survival targets in first-line kidney cancer

s VEGF-targeting Inlyta (axitinib), showing that the duo improved overall survival (OS) and progression-free survival (PFS) compared to Pfizer’s Sutent (sunitinib). ... Pfizer when it presents the JAVELIN Renal 101 study of its PD-1 drug Bavencio
Merck’s Bavencio joins first-line kidney cancer face-off

The JAVELIN Renal 101 study reported at this week’s ESMO conference paired Merck’s immuno-oncology drug Bavencio (avelumab) with Pfizer’s tyrosine kinase inhibitor Inlyta (axitinib), and revealed a ... Combine that with the positive data reported

More from news
Approximately 6 fully matching, plus 20 partially matching documents found.

Latest Intelligence

The handover: Pfizer reshapes itself for a new era

The therapy area is dominated by Merck’s Keytruda, BMS’ Opdivo and Roche’s Tecentriq, but Pfizer is hoping that combinations such as its own Inlyta and Bavencio can help it ... The JAVELIN Renal 101 trial combining Bavencio with Inlyta in
Cancer immunotherapy: What's on the horizon?

They include Pfizer’s OX40 agonist PF-04518600, in early-stage testing in combination with the company’s Bavencio (avelumab) and targeted cancer drug Inlyta (axitinib) as well as chemotherapy,

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

Mirna hires former Pfizer director as CMO

Mirna will be banking on Dr Kim's extensive experience in oncology, which includes serving as global clinical lead for kidney cancer drugs Inlyta (axitinib) and Torisel (temsirolimus) during his time

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

A stumble, but not a fall – what’s next for Opdivo?

Back then, the UK’s cost-effectiveness watchdog NICE deemed Opdivo too pricey for renal cell carcinoma when taking into account the availability of Pfizer's Inlyta at a markedly lower
Oncology drugs under AMNOG

A benefit was found for Inlyta compared with Nexavar in the cytokine treatment group, on the basis of increased tolerability. ... of benefit in one category for these patients was enough to send Inlyta to negotiations for pricing.

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Project/ Events Manager – Medical Education and Events Agency: Salary TBC

Account/ Project Director – Medical Affairs – Surrey: Salary TBC

AD – Corporate Comms/ Public Affairs/ B2B – Healthcare Focus: Salary TBC

Editorial Assistant Medical Education Agency: £25, 000 - £26, 000

Senior Medical Writer: Up to £50, 000 with Benefits

Project Manager/ Account Manager: Salary TBC

Senior Medical Writer: Salary TBC

Senior Planner – Healthcare Advertising – New Role: Salary TBC

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Account Director, Healthcare Marketing Agency: Salary TBC

Account Manager, MedicalCommunications/ Healthcare PR: benefits

Account Director, Medical Education: Salary TBC

PR Director – Health & Wellbeing – Mat Cover (4 days a week)...: Salary TBC

Digital Account Director: Salary TBC

Senior Medical Writer: Great salary and benefits

Subscribe to our email news alerts

PMHub

Add my company

Atlantis Healthcare

Atlantis Healthcare is a global leader in optimising patient self-management. Established in 1996, we design, develop and implement scalable solutions...

Latest intelligence

The importance of co-creation with patients: Overcoming the barriers...
Three billboards on the road to multichannel: Chris Ross examines the trends driving multichannel communication in 2019...
How Medisafe is using AI to improve patient adherence: Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....